It should be the discretion of individual physicians, not insurance companies or pharmacies, to substitute a branded biologic for a biosimilar, which goes back to putting the physician in the decision making process, not the non clinical analyzers. While the search for "cheap" continues...
Posted to
The Medical Quack .... by Barbara Duck
on 08-14-2008
Filed under: Medically Related, Technology, My Commentaries, DNA, Genomics, Biotech, Research, Congress, Pharmaceuticals, Biosimilars
Yesterday I posted about Bank of American hiring more research analysts in the area of healthcare investing and and also stated that Blogs are now becoming part of the research process , I have found several who read this blog. This page relates back to a a post about the commitment of the DeCode...
Posted to
The Medical Quack .... by Barbara Duck
on 07-15-2008
Filed under: Medically Related, Technology, My Commentaries, Genetics, DNA, Genomics, healthcare, Investors, Research, Pharmacogenomics